Summary of the key drugs used for the treatment of multidrug-/extensively drug-resistant tuberculosis (TB)
| Chemical class | Mechanism of action | Details | |
| New drugs | |||
| Bedaquiline (TMC-207) | Diarylquinoline | Inhibits mycobacterial ATP synthase | Clinical development (phase III) Approved by US Food and Drug Administration and European Medicines Agency Included in WHO group 5 drugs |
| Delamanid (OPC-67683) | Nitroimidazole | Inhibits mycolic acid cell wall | Clinical development (phase III) Approved by European Medicines Agency Included in WHO Group 5 drugs |
| Sutezolid (PNU-100480) | Oxazolidinone | Inhibits microbial protein synthesis by blocking 50S ribosomal subunit | Clinical development (phase II) |
| AZD-5847 | Oxazolidinone | Inhibits microbial protein synthesis by blocking 50S ribosomal subunit | Clinical development (phase II) |
| PA-824 | Nitroimidazole | Inhibits cell wall synthesis | Clinical development (phase IIb) |
| SQ-109 | Ethylenediamine | Inhibits cell wall synthesis | Clinical development (phase II) |
| Drugs originally developed with different indications than TB | |||
| Clofazimine | Riminophenazine | Binds to mycobacterial DNA (disrupting the cell cycle) and to bacterial potassium transporters, thereby inhibiting their function | Clinical development (phase II) |
| Included in WHO Group 5 drugs | |||
| Linezolid | Oxazolidinone | Inhibits microbial protein synthesis by blocking 50S ribosomal subunit | Clinical development (phase II) Included in WHO Group 5 drugs |
| Moxifloxacin | Fluoroquinolone | Inhibits DNA gyrase | Clinical development (phase III) Included in WHO Group 3 drugs |
WHO: World Health Organization.